Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Frenzel

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|May 12, 2026
Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AMLCarolin S Joisten, Sibylle C Mellinghoff, Danila Seidel, et al.
Oncogene|April 10, 2012
Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapiesIlya Leskov, Christian P Pallasch, Adam Drake, et al.
The EMBO Journal|December 21, 2021
BCL-2-family protein tBID can act as a BAX-like effector of apoptosisHector Flores-Romero, Lisa Hohorst, Malina John, et al.
Cancer Research|June 20, 2012
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemiaConstance Baer, Rainer Claus, Lukas P Frenzel, et al.
Science Translational Medicine|June 14, 2013
Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumorsArina Riabinska, Mathias Daheim, Grit S Herter-Sprie, et al.
Blood|August 21, 2009
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemiaChristian Philipp Pallasch, Michaela Patz, Yoon Jung Park, et al.
Cell|February 4, 2014
Sensitizing protective tumor microenvironments to antibody-mediated therapyChristian P Pallasch, Ilya Leskov, Christian J Braun, et al.
Nature Communications|April 18, 2023
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Nature Communications|July 29, 2017
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaGero Knittel, Tim Rehkämper, Darya Korovkina, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|May 12, 2026
Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AMLCarolin S Joisten, Sibylle C Mellinghoff, Danila Seidel, et al.
Oncogene|April 10, 2012
Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapiesIlya Leskov, Christian P Pallasch, Adam Drake, et al.
The EMBO Journal|December 21, 2021
BCL-2-family protein tBID can act as a BAX-like effector of apoptosisHector Flores-Romero, Lisa Hohorst, Malina John, et al.
Cancer Research|June 20, 2012
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemiaConstance Baer, Rainer Claus, Lukas P Frenzel, et al.
Science Translational Medicine|June 14, 2013
Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumorsArina Riabinska, Mathias Daheim, Grit S Herter-Sprie, et al.
Blood|August 21, 2009
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemiaChristian Philipp Pallasch, Michaela Patz, Yoon Jung Park, et al.
Cell|February 4, 2014
Sensitizing protective tumor microenvironments to antibody-mediated therapyChristian P Pallasch, Ilya Leskov, Christian J Braun, et al.
Nature Communications|April 18, 2023
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Nature Communications|July 29, 2017
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaGero Knittel, Tim Rehkämper, Darya Korovkina, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Pageof 5